CD8A and neoplasm: In addition, some tumor cells may express inhibitory molecules, such as programmed cell death ligand 1 (PD-L1, an immune checkpoint ligand), which binds to its receptor, PD-1, and inhibits the signal 2-based activation of CD8+ T cells.